Advertisement
Screener

Kiniksa Pharmaceuticals International, plc (KNSA) Dividend Safety

Kiniksa Pharmaceuticals International, plc (KNSA) Dividend Safety

  • Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-03-31..

Dividend safety

Overview →

Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.

MetricValueFormula and calculation
Dividend payout ratio · 12 months(m)Cash dividends paid / net income. Period ending 2026-03-31.

Calculation unavailable: missing inputs remain (m).

Calculation inputs

InputAmount with unitRaw financial data
Dividend payments · 12 months(m)
Net income · 12 months73.06M USDNet Income (Loss) Attributable to Parent

Calculated history

Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.

Period endingDividend payments · 12 months (USD)Net income · 12 months (USD)Dividend payout
2026-03-31(m)$73.06M(m)
2025-12-31(m)$59.01M(m)
2025-09-30(m)$35.92M(m)
2025-06-30(m)$4.79M(m)
2025-03-31(m)$-16.95M(m)
2024-12-31(m)$-43.19M(m)
2024-09-30(m)$-9.07M(m)
2024-06-30(m)$-10.23M(m)
2024-03-31(m)$8.65M(m)
2023-12-31(m)$14.08M(m)
2023-09-30(m)$-6.69M(m)
2023-06-30(m)$231.26M(m)
2023-03-31(m)$196.30M(m)
2022-12-31(m)$183.36M(m)
2022-09-30(m)$142.57M(m)
2022-06-30(m)$-112.07M(m)
2022-03-31(m)$-133.65M(m)
2021-12-31(m)$-157.92M(m)
2021-09-30(m)$-175.25M(m)
2021-06-30(m)$-188.54M(m)
2021-03-31(m)$-184.45M(m)
2020-12-31(m)$-161.38M(m)
2020-09-30(m)$-139.52M(m)
2020-06-30(m)$-122.74M(m)
2020-03-31(m)$-122.47M(m)
2019-12-31(m)$-161.87M(m)
2019-09-30(m)$-172.65M(m)
2019-06-30(m)$-170.00M(m)
2019-03-31(m)$-153.07M(m)
2018-12-31(m)$-103.23M(m)
2018-09-30(m)(m)(m)
2018-06-30(m)(m)(m)
2018-03-31(m)(m)(m)
2017-12-31(m)$-64.87M(m)
2017-09-30(m)(m)(m)
2017-06-30(m)(m)(m)

(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.